LAG3 and cancer: Despite its significant therapeutic potential in cancer immunotherapy and the substantial attention it has received from academia and industry, the molecular mechanisms of LAG3-mediated immunosuppression remain poorly understood, primarily because of its unique ligand-binding characteristics and intracellular domains[1].